Healthcare Contract Research Outsourcing Market (Service: Clinical Trial Service, Regulatory Services, Clinical Data Management & Biometrics, Medical Writing, Pharmacovigilance, Site Management Protocol, and Others; Therapeutic Area: Oncology/Hematology, CNS, CV/Metabolic, Respiratory, Infectious Diseases, Immunology, Rare Diseases, Medical Devices, and Others; and End-user: Pharmaceutical Companies, Biotechnology Companies, Medical Device Companies, and Academic Institutes & Government Organizations) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Healthcare Contract Research Outsourcing Market 

5.1. COVID-19 Landscape: Healthcare Contract Research Outsourcing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Healthcare Contract Research Outsourcing Market, By Service

8.1. Healthcare Contract Research Outsourcing Market, by Service, 2022-2030

8.1.1 Clinical Trial Service

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Regulatory Service

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Clinical Data Management & Biometrics

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Medical Writing

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. Pharmacovigilance

8.1.5.1. Market Revenue and Forecast (2017-2030)

8.1.6. Site Management Protocol

8.1.6.1. Market Revenue and Forecast (2017-2030)

8.1.7. Others

8.1.7.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Healthcare Contract Research Outsourcing Market, By Therapeutic Area

9.1. Healthcare Contract Research Outsourcing Market, by Therapeutic Area, 2022-2030

9.1.1. Oncology / Hematology

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. CNS

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. CV / Metabolic

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Respiratory

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Infectious Diseases

9.1.5.1. Market Revenue and Forecast (2017-2030)

9.1.6. Immunology

9.1.6.1. Market Revenue and Forecast (2017-2030)

9.1.7. Rare Diseases

9.1.7.1. Market Revenue and Forecast (2017-2030)

9.1.8. Medical Devices

9.1.8.1. Market Revenue and Forecast (2017-2030)

9.1.9. Others

9.1.9.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Healthcare Contract Research Outsourcing Market, By End-user 

10.1. Healthcare Contract Research Outsourcing Market, by End-user, 2022-2030

10.1.1. Pharmaceutical Companies

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Biotechnology Companies

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Medical Device Companies

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Academic Institutes & Government Organizations

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Healthcare Contract Research Outsourcing Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Service (2017-2030)

11.1.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.1.3. Market Revenue and Forecast, by End-user (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Service (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.1.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Service (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.1.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Service (2017-2030)

11.2.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.2.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Service (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.2.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Service (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.2.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Service (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.2.6.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Service (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.2.7.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Service (2017-2030)

11.3.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.3.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Service (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.3.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Service (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.3.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Service (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.3.6.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Service (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.3.7.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Service (2017-2030)

11.4.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Service (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.4.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Service (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.4.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Service (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.4.6.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Service (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.4.7.3. Market Revenue and Forecast, by End-user (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Service (2017-2030)

11.5.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Service (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.5.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Service (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.5.5.3. Market Revenue and Forecast, by End-user (2017-2030)

Chapter 12. Company Profiles

12.1. PAREXEL International

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. ICON plc

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. PRA Health Sciences, Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Charles River

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Laboratory Corporation of America Holdings (Covance)

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. IQVIA

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. IQVIA

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Pharmaceutical Product Development, LLC.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms